drugset / Trial / NCT00383266
A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer
Phase 2
Terminated
9 enrolled
Washington University School of Medicine
Eli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a study of an investigational agent, pemetrexed, in combination with a standard chemotherapy drug, carboplatin, for treatment of patients with metastatic esophageal cancer.
Timeline
- Start
- 2006-10
- Primary completion
- 2009-11
- Completion
- 2010-06
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |